Biogen dips as strategy post Alzheimer’s setback fails to impress

By

Biogen dips as strategy post Alzheimer's setback fails to impress

Biogen on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer’s drug.

Source: Business News –

MustHaves.LA a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for us to earn fees by linking to Amazon.com and affiliated sites.